• 2014–2017 — Обучение по программе узкой медицинской специализации (субспециализация)
• 2009–2013 — Обучение в ординатуре (специализация)
• 2002–2008 — Медицинский факультет, Университет Диджле (медицинское образование)

• Персонализированная таргетная терапия


• Иммунотерапия


• Онкология лёгких


• Онкология молочной железы


• Колоректальная онкология


• Онкология предстательной железы


• Онкология желудка и пищевода


• Онкология почек и мочевого пузыря


• Гинекологическая онкология


• Опухоли головного мозга, головы и шеи


• Нутритивная и поддерживающая терапия в онкологии

• 2023–2026 — Городская больница имени д-ра Лютфи Кырдара, Картал

• 2019–2023 — Больница VM Medical Park Коджаэли

• 2017–2019 — Учебно-исследовательская больница имени д-ра Эрсина Арслана, Газиантеп

• 2013–2014 — Региональная государственная больница Батмана

• 2008–2009 — Станция службы скорой медицинской помощи № 5 (112), Диярбакыр

Международные научные публикации

2025

• Altıntaş YE, Kınıkoğlu O, Işık D и соавт. Very Favorable vs. Favorable Risk Groups in Metastatic Renal Cell Carcinoma: A Step Toward Personalized Treatment. Cancers, 2025. (Q1)


• Kınıkoğlu O, Işık D. Evaluating the Performance of ChatGPT-4o Oncology Expert in Comparison to Standard Medical Oncology Knowledge: A Focus on Treatment-Related Clinical Questions. Cureus, 2025.


• Topal A, Akdağ G, Yıldırım S, Işık D и соавт. Efficacy and Clinical Outcomes of Crizotinib in Patients with ROS1-Rearranged NSCLC: A Multicenter Study. Medicina, 2025. (Q1)

2024

• Işık D, Kınıkoğlu O. Prognostic and Molecular Characterization of Metastatic Transverse Colon Cancer: Insights From a Single-Center Retrospective Study. Cureus, 2024.


• Kınıkoğlu O, Odabaş H, Altıntaş YE, Işık D и соавт. Combining Endocrine Therapy with Trastuzumab Emtansine Improves Progression-Free Survival and Overall Survival in HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer. Medicina, 2024. (Q1)


• Yıldırım S, Doğan A, Akdağ G, Işık D и соавт. The Role of Laboratory Indices on Treatment Response and Survival in Breast Cancer Receiving Neoadjuvant Chemotherapy. Scientific Reports, 2024. (Q1)


• Kahraman S, Karakaya S, Kaplan MA, Işık D и соавт. Treatment Outcomes and Prognostic Factors in Patients with Driver Mutant Non-Small Cell Lung Cancer and De Novo Brain Metastases. Scientific Reports, 2024. (Q1)


• Akdağ G, Alan Ö, Doğan A, Işık D и соавт. Prognostic Scores in Pulmonary Large Cell Neuroendocrine Carcinoma: A Retrospective Cohort Study. Heliyon, 2024. (Q1)


• Akdağ G, Doğan A, Yıldırım S, Işık D и соавт. Exploring the Clinical Impact of RANK Pathway Inhibition in Advanced Breast Cancer. Cureus, 2024.


• Kahraman S, Hizal M, Işık D и соавт. Activity of CDK4/6 Inhibitors and Parameters Affecting Survival in Elderly Patients. BMC Cancer, 2024. (Q2)


• Yıldırım S, Doğan A, Akdağ G, Işık D и соавт. Lymphocyte-to-Albumin Ratio Predicts Survival in Metastatic NSCLC Patients. Cancers, 2024. (Q1)


• Akdağ G, Alan Ö, Doğan A, Işık D и соавт. Efficacy and Safety of Ixabepilone in Metastatic Breast Cancer After Multiple Treatments. Journal of Oncological Sciences, 2024.


• Altıntaş YE, Kınıkoğlu O, Yıldız A, Işık D и соавт. Trastuzumab Rechallenge in HER2-Positive Metastatic Breast Cancer. Medicina, 2024. (Q1)


• Işık D, Alan Ö, Akdağ G и соавт. Evaluating the Effectiveness of Nivolumab in Metastatic Lung Cancer Among Patients Aged 65 and Older. Journal of Clinical Medicine, 2024. (Q1)


• Yıldırım S, Alan Ö, Yüksel YZ, Işık D и соавт. Prognostic Impact and Clinical Features of Spread Through Air Spaces in Operated Lung Cancer. Medicina, 2024. (Q1)


• Akdağ G, Işık D, Doğan A и соавт. Does Adjuvant Chemotherapy Benefit Patients with T4 N0 Colon Cancer? Medicina, 2024. (Q1)


• Işık D, Kınıkoğlu O, Akdağ G и соавт. Clinical Effectiveness of Targeted Therapies Following Nivolumab Therapy in Metastatic Renal Cell Carcinoma. Medicina, 2024. (Q1)


• Gürler F, Tay F, Işık D и соавт. Neoadjuvant Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma. Cancer Medicine, 2024. (Q2)


• Akdağ G, Yıldırım S, Doğan A, Işık D и соавт. Neoadjuvant Chemotherapy and Pathologic Complete Response in HR+/HER2− Breast Cancer. Chemotherapy, 2024. (Q3)

2023 и ранее

• Işık D, Koca D. XLOT Regimen Instead of FLOT Regimen in Gastric Cancer. Journal of Cancer Research and Therapeutics, 2023.


• Kahraman S, Urul E, Işık D и соавт. Treatment Efficacy of Ribociclib or Palbociclib Plus Letrozole in Metastatic Breast Cancer. Future Oncology, 2023.


• Karaçin C, Işık D и соавт. Efficacy of Subsequent Treatments in Patients with Hormone-Positive Advanced Breast Cancer. BMC Cancer, 2023.


• Bahçeci A, Paydaş S, Işık D и соавт. Efficacy and Safety of Trastuzumab Emtansine in HER2 Positive Metastatic Breast Cancer. Cancer Investigation, 2021.


• Bahçeci A, Kötek SA, Işık D. The Prognostic Values of Prognostic Nutritional Index in Extensive-Stage Small Cell Lung Cancer. Anti-Cancer Drugs, 2021.


• Kefeli U, Kaymaz S, Aydın D, Işık D и соавт. Adjuvant Chemotherapy in Elderly Patients with Early-Stage Non-Small Cell Lung Cancer. Bezmialem Science, 2019.


• Aydın D, Şendur MA, Işık D и соавт. Evaluation of Bevacizumab in Advanced Small Bowel Adenocarcinoma. Clinical Colorectal Cancer, 2017.


• Özçelik M, Korkmaz T, Odabaş H, Işık D и соавт. Comparison of Chemotherapy Regimens in Inoperable Stage III Non-Small Cell Lung Cancer. Tumor Biology, 2016.


• Aydın D, Bilici A, Yavuzer D, Işık D и соавт. Prognostic Significance of ADAM17 Expression in Gastric Cancer. Clinical & Translational Oncology, 2015.


• Özçelik M, Odabaş H, Işık D и соавт. Capecitabine Plus Bevacizumab Combination in Elderly Metastatic Colorectal Cancer Patients. Clinical & Translational Oncology, 2015.

Национальные публикации

• Efficacy and Safety of CDK4/6 Inhibitor Therapy in Patients Aged 70 and Older with Metastatic Breast Cancer: A Retrospective Single Center Analysis. Southern Clinics of Istanbul Eurasia, 2025.


• The Clinical Significance of Fibrinogen-Like Protein 2 (FGL-2) Levels in Nonalcoholic Steatohepatitis. Southern Clinics of Istanbul Eurasia, 2024.


• The Prevalence and Prognostic Relevance of ABO/Rh Blood Groups in Metastatic Breast Cancer Patients Undergoing CDK4/6 Inhibitor Therapy. Eurasian Journal of Medical Investigation, 2024.


• Factors Affecting Recurrence in Transverse Colon Tumors: A Single-Center Study. Southern Clinics of Istanbul Eurasia, 2024.


• Male Breast Cancer in a Single-Center Experience: Diagnosis, Clinicopathological Features and Treatment Strategies. İstanbul Kuzey Klinikleri, 2024.

Главы в книгах

• Современные подходы к лечению в онкологии (2019) — Терапия ингибиторами тирозинкиназы при раке щитовидной железы.


• Опухоли желудочно-кишечного тракта – 1 (2019) — Молекулярно-таргетная терапия при метастатическом раке желудка.


• Онкология (2018) — Гинекологические онкологические заболевания.

Научные конгрессы и доклады

• Мультидисциплинарный конгресс по опухолям головы и шеи (2025)


• Симпозиум по раку молочной железы (2025)


• Симпозиум «Инновации в онкологии» (2024)


• Симпозиум «Инновации в онкологии» (2023)


• Турецкий конгресс медицинской онкологии (2023)


•